Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

PRE-ACT

Financiado

Cerrado

PRE ACT Prediction of Radiotherapy side Effects using explainable AI for patien...

PRE ACT Prediction of Radiotherapy side Effects using explainable AI for patient Communication and Treatment modification Radiotherapy is a widely used cancer treatment, however some patients suffer side effects. In breast cancer, side effects can include breast atrophy, arm lymphedema, and heart damage. Some factors that increase risk for side effec... ver más

30/09/2027

National Gallery o...

5M€

Presupuesto del proyecto: 5M€

Líder del proyecto

National Gallery of Athens - Alexandros Souts... No se ha especificado una descripción o un objeto social para esta compañía.

Fecha límite participación Sin fecha límite de participación.

Ver 12 Participantes

Financiación concedida El organismo HORIZON EUROPE notifico la concesión del proyecto el día 2022-05-23

HORIZON-HLTH-2021-DISEASE-04-04: Clinical validation of artificial i... ExpectedOutcome:This topic aims at supporting activities that are enabling or contributing to one or...

I+D

Cerrada hace 3 años

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

12 Participantes

National Gallery of Athens -...

637.24K€ | Lider

CENTAI

535.63K€ | Participante

THERAPANACEA

N.D. | Participante

Mirada Medical

N.D. | Participante

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Proyectos interesantes

OPTIMA Optimal treatment for patients with solid tumours in Europe... 23M€ Cerrado

CLARIFY Cancer Long Survivors Artificial Intelligence Follow Up 5M€ Cerrado

4D PICTURE Design-based Data-Driven Decision-support Tools: Producing I... 9M€ Cerrado

CHAIMELEON Accelerating the lab to market transition of AI tools for ca... 9M€ Cerrado

I3LUNG Integrative science, Intelligent data platform for Individua... 10M€ Cerrado

PRO-ORATICA PRedictive mOdeling Of RAdiaTion Induced CArdiotoxicity afte... 161K€ Cerrado

Duración del proyecto: 64 meses Fecha Inicio: 2022-05-23
Fecha Fin: 2027-09-30

Líder del proyecto

National Gallery of Athens - Alexandros Souts... No se ha especificado una descripción o un objeto social para esta compañía.

Presupuesto del proyecto 5M€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Radiotherapy is a widely used cancer treatment, however some patients suffer side effects. In breast cancer, side effects can include breast atrophy, arm lymphedema, and heart damage. Some factors that increase risk for side effects are known, but current approaches do not use all available complex imaging and genomics data. The time is now ripe to leverage the huge potential of AI towards prediction of side effects. This project will use rich datasets from three patient cohorts to design and implement an AI tool that predicts the risk of side effects, including arm lymphedema in breast cancer patients and provides an easily understood explanation to support shared decision-making between the patient and physician. The PRE-ACT consortium combines the expertise in computing (MDW, AUEB-RC), AI (HES-SO, CENTAI), radiation oncology (MAASTRO, UNICANCER), medical physics (THERA), genetics (ULEIC), psychology (CNR) and health economics (UM) that is necessary to tackle this problem. The project will integrate data from the three cohorts and build AI predictive models with built-in explainability for each of the key side effects of breast cancer radiotherapy. These AI models will be incorporated into an existing commercial radiotherapy software platform to create a world-leading product. The extended platform will be validated in a clinical trial to support treatment decisions regarding the irradiation of lymph nodes. The trial will adopt an innovative design in which the patients and medical team in the test arm will receive the risk prediction, but those in the control arm will not. A communication package built with a co-design methodology will ensure that AI outcomes are tailored to stakeholders effectively. The trial will evaluate whether using the AI platform changed the arm lymphedema rate and impacted treatment decisions and quality-of-life. Generalizability of the AI models for other types of cancer will be sought through transfer learning techniques.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores